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Abstract: To elucidate clinical trial efficacy, safety, and dosing
practices of AbobotulinumtoxinA (ABO) treatment in adult patients
with lower limb spasticity.
A systematic literature review was performed to identify random-
ized controlled trials of ABO in the treatment of adult lower limb
spasticity.
Of the 295 records identified, 6 primary publications evaluated ABO
for the management of lower limb spasticity of various etiologies and
were evaluated. Total ABO doses ranged between 500 and 2000 U for
lower limb spasticity, depending on the muscles injected. All studies in
lower limb spasticity showed statistically significant reduction in
muscle tone based onModified Ashworth Scale of ABO versus placebo.
Significant effects on active movement and pain were demonstrated
albeit less consistently. ABO was generally well tolerated across the
individual studies; most adverse events reported were considered
unrelated to treatment. Treatment-related adverse events included but
not limited to fatigue, local pain at injection site, hypertonia, dry mouth,
weakness of the noninjected muscle, abnormal gait, and urinary tract
infection.
These data from 6 randomized clinical studies provide thehen, PharmD, Hea r, MD,
ee, MD, MHA
(Medicine 95(2):e2468)
Abbreviations: ABO = AbobotulinumtoxinA, ALLS = adult lower
limb spasticity, AULS = adult upper limb spasticity, BoNT =
botulinum neurotoxin, MAS = Modified Ashworth Scale.
INTRODUCTION
A dult lower limb spasticity (ALLS) is 1 of the disablingcomplications of multiple-neurological disorders such as
stroke, multiple sclerosis, spinal cord injury, and even some
central neurodegenerative disorders. People with ALLS can
present with a variety of abnormal postures; the most common
lower limb postures being spastic drop foot with hyper plantar
flexion, equinovarus, knee flexion or hyperextension, and toe
flexion.1 The increased tone due to spasticity can cause sig-
nificant discomfort, and patients describe it as a leg spasm,
cramp or dull pain. In many cases, ALLS can be more disabling
than adult upper limb spasticity (AULS) because even mild
spasticity can significantly affect patients’ stride, gait, and
balance. If left unmanaged, patients with ALLS are often
predisposed to secondary complications of reduced mobility
such as tendon shortening, joint deformity, and eventually
immobilization.2 These secondary complications can them-
selves cause more systemic complications including deep vein
thrombosis3 and pressure ulcers.4
The integral role of botulinum neurotoxin (BoNT) in the
management of focal spasticity is recognized by guidelines
from around the world.5–7 At present, there is no FDA approved
botulinum toxin for the treatment of lower limb spasticity in the
United States. On the other hand, there is an accumulating body
of evidence to support efficacy and safety of BoNT in managing
ALLS. Although most literature reviews examine the effective-
ness of all BoNT products as a class, the differences in dosing
units and recommended schemes provide a clear rationale for
reviewing the efficacy, safety, and dosing information for each
product separately. We have previously reported on a systema-
tic review evaluating the effectiveness of AbobotulinumtoxinA
(ABO) in the management of AULS8; this report focuses on the
results of a parallel systematic review of clinical studies of ABO
in ALLS.
METHODS
The systematic literature review presented here is 1 part of
a larger systematic review of all potential indications for ABO,
the results of which will be presented separately per each
relevant indication. The literature search strategy and methods
for this systematic review were specified in advance and
documented in a protocol.8 Components of the protocol includeategy, screening criteria, data extraction
bias appraisal used to assess studies
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muscles according to their involvement in spasticity judged by
the injector physician. The range of ABO dosages for individua
muscles were as follows: triceps surae (500–1000 U), soleus
TABLE 1. Etiology of Lower Limb Spasticity
Hyman et al14 Multiple sclerosis (definite o
probable) (100%)
Hesse et al11 Stroke (100%)
Burbaud et al10 Stroke (83%, 19/23)
Ischemic (61%)
Hemorrhage (22%)
Traumatic (17%)
Johnson et al12 Stroke (100%)
13Screening Criteria
Specific study characteristics of interest were defined in
the protocol. They include: study type—randomized controlled
trials and other comparative clinical studies; patient popu-
lation—adult patients with LLS; treatment—ABO; and out-
comes—primary and secondary efficacy, safety, and dosing.
Literature Search Strategy and Data Sources
The literature search strategy was developed using a
combination of Medical Subject Heading (MeSH) terms and
keywords. Keywords of relevance to the review of ALLS were:
AbobotulinumtoxinA (alternative spellings included: Abobotu-
linumtoxin A and Abobotulinum toxin A), Dysport, spasticity,
and clinical trial. Language (English only) and date limits
(January 1991 to January 2013) were also applied.8 Sub-
sequently, the search was updated to include ALLS papers
published between January 2013 and April 2015. The search
was performed in 3 foundational and comprehensive electronic
medical literature databases (PubMed, Cochrane Library, and
Embase). Bibliographic reference lists of systematic reviews
identified during screening were searched to identify any
relevant studies that were not identified through the electronic
database searches.
Study Selection
At level 1 screening, all publications reporting preclinical,
Phase 1, prognostic/biomarker, genetic retrospective, registry,
case report, and/or noncomparative studies were excluded, as
were letters, consensus reports, editorials, and nonsystematic
reviews. Although, systematic reviews and meta-analyses were
not included in their own right, they were used for identification
of additional primary studies. At level 2 screening, all publi-
cations that reported only biochemical or immunologic end-
points were excluded. Also at this stage, nonrandomized,
controlled Phase 2 or 3 clinical trials, comparative long-term
follow-up studies (eg, open-label follow-up of randomized,
controlled clinical trials) and comparative prospective Phase
4 postmarketing trials were excluded, provided that adequate
information from randomized phase 2 and phase 3 trials had
been identified. The systematic literature review process of
study selection was depicted in a PRISMA flow diagram.
Data Extraction
Study methodology, patient, and treatment-level data were
extracted from the full-text publications under predefined head-
ings (eg, efficacy, safety, dosing). Each included study under-
went quality assessment for risk of bias based on Cochrane
metrics. The quality assessment for RCTs systematically
addresses 6 types of bias: selection, performance, detection,
attrition, reporting, and other sources of bias not covered by
other domains. If non-RCTs or other study types were deemed
relevant for data extraction, quality assessment was performed
using Transparent Reporting of Evaluations with Nonrando-
mized Designs (TREND) appraisal criteria for non-RCTs.9
Role of the Funding Source
The study was partially funded by Ipsen for data collection
and editorial support. KD developed the protocol and data
collection was coordinated by RTI Health Solutions and desig-
Dashtipour et alnates. Aside from procuring the data collection and editorial
support, Ipsen did not contribute to the study conduct or
reporting of results. All authors had full access to all data,
2 | www.md-journal.comcontributed to manuscript revisions, and had final approval for
submission. KD wrote the initial draft and had final responsi-
bility for the decision to submit the paper for publication. JJC
wrote the revision draft.
RESULTS
Publications Identified
A total of 295 records were identified from the medical
literature databases. Of these, 6 primary publications that
evaluated ABO for the management of ALLS in adult patients
were included in the final data report (Table 1).10–15 Figure 1
shows the PRISMA diagram for the full systematic review of all
randomized controlled trials of ABO. With the exception of the
study by Burbaud et al,10 that was judged high risk, most of
studies included in this report fulfilled criteria for low-risk
selective reporting bias (Supplementary Table). Studies used
a wide range of outcome measures including measures of
spasticity (usually assessed with the Modified Ashworth Scale;
MAS), range of movement (passive and active), walking
parameters, pain, global clinical impression, activities of daily
living, and goal attainment.
Efficacy in ALLS
Statistically significant reductions in muscle tone versus
baseline were reached for the majority of evaluations using
MAS. When assessed, ABO treatment was consistently associ-
ated with significant effects on pain. Effects on walking
parameters were less consistent but generally favored ABO
injections. Table 2 provides an overview of efficacy and safety
outcomes from each of the studies.
Burbaud et al10 evaluated the efficacy and safety of ABO
in 23 hemiparetic patients with spasticity of the ankle plantar
flexors and foot invertors due to stroke or traumatic hemiparesis
in a randomized double blind, placebo controlled crossover
study.10 Patients received 1 injection of ABO and 1 of placebo
in random order at day 0 and day 90. Injections were performed
with electromyographic (EMG) guidance. Treatment efficacy
was subjectively assessed by patients (on a scale of 0–3) and
objectively assessed using clinical rating scales (assessing
active dorsiflexion in the supine, sitting and standing position,
and gait). The MAS and the Fugl–Meyer scale for the inferior
limb were also applied. Treatment was with 1000 U ABO
(diluted with 5 mL saline) and distributed among the various
Medicine  Volume 95, Number 2, January 2016Pittock et al Stroke (100%)
Gusev et al15 Multiple sclerosis (definite o
probable) (100%)
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reservedl
rr
.
TABLE 2. Evidence Table of Completed Trials for Lower Limb Spasticity
Study Identifier
Design, Objective
Patient Population, 
Sample Size
Intervention Efficacy Outcomes Safety Outcomes
Burbaud et al., 
1996
Design: 
Randomized, double-
blind placebo-
controlled trial 
(cross-over)
Objective: 
To confirm the 
apparent 
effectiveness of ABO 
in hemiparetic 
patients with ankle 
plantar flexor and 
foot inverter 
spasticity 
Patient population:
Poststroke and 
traumatic hemiparesis 
foot spasticity 
Sample size:
N = 23
Intervention:
Arm 1: ABO (1,000 
U) first
Arm 2: PBO first
Note: Each arm 
received ABO and PBO; 
however, the order of 
injection was random
Primary outcome: 
Improvement (patient perception) 
87% of ABO-treated patients reported improvement; the subjective score 
increased by 2 points in 65% of those who reported improvement
ABO-treated patients reported significantly greater improvement compared 
with PBO-treated patients (P = 0.004)
Influence of first injection 
PBO injection day 0, ABO injection day 90
Slight, but NS evolution in gait velocity and Ashworth ankle scores with 
PBO between day 0 to 90 sessions (P value NR)
Except for gait velocity, all clinical scores significantly improved between 
day 90 and day 120 (P = 0.01)
ABO injection day 0, PBO injection day 90
Significant improvement in video (P = 0.0103) and Fugl-Meyer score 
(P = 0.0067) found between day 0 and day 90 (but not day 120)
Between day 0 and day 30, significant improvement was found in ankle 
scores (Ashworth extensors, Ashworth inverters, and active dorsiflexion) 
(P < 0.0001)
Significance sustained through day 90 and day 120 for both extensor 
(P = 0.0067, P = 0.0058), and inverter (P = 0.0087, P = 0.0114) Ashworth 
scores
Improvement in dorsiflexion scores was not sustained from day 0 to day 90 
or day 120 (NS, P = 0.2964; P = 0.2616)
Evolution of clinical ratings: pooled data 1 month 
post–ABO injection (n = 23)
Clinical scales
Before ABO 
(n = 23)
mean (SD)
After ABO
(n = 23)
mean (SD)
Video score (0-4) 3.1 (0.6) 2.0 (0.6)***
Gait velocity (cm/s) 25.1 (17.1) 29.4 (16.4)
Fugl-Meyer score 23.5 (4.9) 25.0 (4.7)*
Ashworth ankle 
extensors
3.7 (0.7) 2.4 (0.9)***
Ashworth ankle 
invertors
2.8 (0.9) 1.8 (0.9)***
Active ankle 
dorsiflexion 
(global score 0-6)
2.2 (1.5) 3.3 (1.4)***
*P < 0.05; ***P < 0.001. 
Significant improvement for all clinical rating scales, except gait velocity, was 
observed after ABO injection.
Influence of severity and duration of spasticity on ABO efficacy
Clinical 
improvement
Ashworth ankle 
extensors
Subjective 
score mean
Ankle Ashworth 
score < 7 (n = 11)
1.3 (0.6) 1.5 (0.8)
Ankle Ashworth 1.4 (0.9) 1.4 (0.8)
Safety outcomes:
No general or local side 
effects were reported by 
patients except for local 
pain at injection site 
(n = 3)
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TABLE 2. (Continued)
Study Identifier
Design, Objective
Patient Population, 
Sample Size
Intervention Efficacy Outcomes Safety Outcomes
Hesse et al., 1995
Design: 
Randomized, active 
controlled, clinical 
trial
Objective: 
To determine 
whether additional 
electrical stimulation 
enhances the 
effectiveness of ABO 
in the treatment of 
unilateral lower-limb 
spasticity following 
stroke
Patient population:
Poststroke lower-limb 
spasticity
Sample size:
N = 10
Intervention:
Arm 1: EMG-guided 
ABO injection (2,000 
U)
Arm 2: EMG-guided 
ABO (2,000 U for 
first patient only; 
1,500 U for 
remaining patients) 
+ neuromuscular 
stimulation
Note: Due to AEs in 
Arm 2, patient 1, the 
dose for subsequent 
patients in Arm 2 was 
reduced
Primary outcomes: 
Muscle tone (MAS)
Arm 1:ABO (2,000 U) only
25% (1 of 4) patients in the ABO alone reported a slight improvement in 
MAS—reduction of 1 point (P values NR) 
Minor qualitative improvement in cyclogram 
No change was observed in other subjective or functional parameters (P
values NR)
The toxin caused no plantar weakness in Arm 1
Arm 2: ABO (1,500 U) + neuromuscular stimulation
Reduction of 1 point in MAS was observed in 40% (2 of 5) of patients (P
values NR)
Reduction of 2 points in MAS was observed in 60% (3 of 5) (P values NR)
Cyclogram showed qualitative improvement in all patients who received 
neuromuscular stimulation
The toxin caused plantar weakness in all patients Arm 2
Pre- and post-gait variables
Gait variables
Pre 
Mean (SD)
Post
Mean (SD)
Velocity (m/s)
ABO alone 0.28 (0.11) .30 (0.10)
ABO + neuromuscular 
stimulation
0.39 (0.37) 0.49 (0.40)*
Stride (m)
ABO alone 0.56 (0.11) 0.58 (0.14)
ABO + neuromuscular 
stimulation
0.64 (0.33) 0.77 (0.37)*
Cadence (steps/min)
ABO alone 60 (13.8) 62.1 (10.8)
ABO + neuromuscular 
stimulation
58.5 (31.2) 67.6 (29.0)
Stance symmetry (%)
ABO alone 72.6 (7.2) 68.0 (9.6)
ABO + neuromuscular 
stimulation
70.0 (14.5) 84.8 (6.8)*
Swing symmetry (%)
ABO alone 56.2 (16.4) 52.0 (23.6)
ABO + neuromuscular 
stimulation
56.0 (24.6) 65.2 (26.6)*
Double support (% cycle 
duration)
ABO alone 53.7 (13.8) 53.4 (16.9)
ABO + neuromuscular 
stimulation
54.9 (22.1) 44.9 (9.3)
* Significant group difference at P < 0.05.
Secondary outcomes: NR
Optimal dosing:
Due to AEs in the first patient in Arm 2 (ABO 2,000 U + neuromuscular 
AEs believed to be 
drug-related:
First patient treated in 
Arm 2 (ABO 2,000 U + 
neuromuscular 
stimulation)
Bladder pareses 
requiring catheterization 
for 14 days
AEs not confirmed to be 
drug-related:
Symptomatic grand mal 
seizures monthly
1 severe seizure 
3 weeks after injection
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TABLE 2. (Continued)
Study Identifier 
Design, Objective 
Patient Population,  
Sample Size 
Intervention Efficacy Outcomes Safety Outcomes 
Johnson et al., 
2004 
 
Design:  
Non-blinded 
randomized 
controlled trial 
 
Objective:  
To investigate the 
effect of combined 
ABO and functional 
electric stimulation 
(FES) treatment on 
spastic drop foot in 
stroke 
Patient population: 
Poststroke spastic drop 
foot 
 
Sample size: 
N = 21 
 
Intervention: 
 Arm 1: PT + ABO 
(1,200 U) + FES 
 Arm 2: PT alone 
Primary outcomes: 
Walking speed  
 Over the 12 weeks, walking speed increased for both control (P = 0.20) 
and treatment groups (PT + ABO + FES: P = 0.042; PT + ABO 
[nonstimulated]: P = 0.004) 
 The overall increase in mean walking speed at 12 weeks relative to controls 
was 0.09 m/s in the PT + ABO + FES group and 0.04 m/s in the PT + ABO 
(nonstimulated) group 
Secondary outcomes: 
 A statistically significant downward trend in median PCI observed for 
treatment groups (PT + ABO + FES: P = 0.020; and PT + ABO 
[nonstimulated]: P = 0.020), but not for the control group (NS, P = 0.292) 
 A downward, but not significant, trend observed in the median MAS of the 
ankle plantar flexors in the treatment group (NS, P = 0.282); no trend 
evident in the control group (NS, P = 0.742) 
 From baseline to week 8, MAS was statistically significant in the treatment 
group (P = 0.022) 
 A downward but not significant trend observed in the median MAS of the 
quadriceps femoris in the treatment group (NS, P = 0.051); no trend 
evident in the control group (NS, P > 0.20) 
 No statistically significant change in median MAS of the hamstrings in 
either treatment group (NS, treatment, P = 0.326; control, P = 0.553)  
 No change in median MAS of the dorsiflexors for either group, where there 
was a median score of 0, representing an absence of spasticity on clinical 
examination 
 A statistically significant upward trend in median RMA (mobile disability) 
total and gross scores was seen in the treatment group (P = 0.024, 
P < 0.001, respectively), but not in the control group (NS, P = 0.200, P > 
0.200, respectively) 
 Leg and trunk sections of the RMA showed no significant difference 
between control or treatment groups (all P > 0.20) 
 No statistically significant trends in any dimension of the SF-36 in either 
control or treatment groups (NS, P value NR)  
Few AEs reported, and 
those that were reported 
are not well described: 
PT-only group (control) 
 Stroke (n = 1) 
 Minor health problems: 
lower back strain and 
seizure (n = 2) 
Treatment (undefined 
treatment group) 
 Headaches possibly due 
to stimulation (n = 1) 
 Intercurrent illness 
(n = 3) 
 Fall, hearing loss, and 
cardiac problems 
(n = 1) 
 
No other AEs were 
reported or considered 
related to study treatment 
Medicine  Volume 95, Number 2, January 2016 Botulinum Toxin in Lower Limb Spasticity
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TABLE 2. (Continued)
Study Identifier
Design, Objective
Patient Population, 
Sample Size
Intervention Efficacy Outcomes Safety Outcomes
Pittock et al., 2003
Design: 
Prospective, 
randomized, double-
blind, placebo-
controlled, dose-
ranging study
Objective: 
To assess the effects 
of three doses of 
ABO on calf spasticity 
causing spastic 
equinovarus 
deformity, and to 
evaluate its impact 
on walking
Patient population:
Poststroke lower-limb 
spasticity
Sample size:
N = 234
Intervention:
Arm 1: PBO
Arm 2: ABO (500 U)
Arm 3: ABO (1,000 
U)
Arm 4: ABO (1,500 
U)
Primary outcome: 
Distance covered during a 2-minute walking test (m)
Time 
points
PBO 
(n = 54)
Mean
ABO
500 U
(n = 55)
Mean
ABO
1,000 U
(n = 55)
Mean
ABO
1,500 U
(n = 57)
Mean
Baseline
4 weeks
8 weeks
12 weeks
41.4
46.5
48.5
50.5
41.4
44.3
49.0
49.5
42.9
46.6
47.8
50.6
40.5
46.0
48.2
48.9
Distance increased significantly (P  0.05) in each of the treatment groups, 
including PBO. No statistically significant difference was observed between 
groups (P > 0.05).
If distance at baseline was less than 30 m, only a small improvement was 
seen in Arms 1, 2, and 3 (~ 4 m), but a greater mean increase (~ 6 m) 
was seen in Arm 4 (P value NR)
If distance at baseline was between 30 and 60 m, a more marked 
improvement was seen in all arms (~ 12 m) (P value NR) 
If distance at baseline was > 90 m, only a small or no change was 
observed in Arm 1 (~ 3 m), Arm 3 (~ 5 m), and Arm 4 (–0.4 m), but a 
greater change was seen in Arm 2 (10 m) (P value NR).
Secondary outcomes:
Stepping rate and step length discrepancy
Increased significantly in each treatment group (P < 0.05), but no 
statistically significant differences between groups (P value NR).
Statistically significant correlation between the baseline discrepancy in step 
length (cm) and the change observed after treatment within each 
treatment group, including PBO, at each time point (4, 8, and 12 weeks: 
Arm 1, P = 0.001, P = 0.0014, P = 0.0002; Arm 2, P = 0.060, P < 0.0001, 
P = 0.0002; Arm 3, P < 0.0001, P < 0.0001, P < 0.0001; Arm 4, P = 
0.0086, P = 0.0036, P = 0.0006)
The greatest reduction in the step length discrepancy was seen in Arm 3 at 
8 weeks after treatment (P < 0.0001)
Rivermead Motor Assessment (RMA)
No statistically significant differences between groups (P value NR).
Use of walking aids
Greatest changes in the need of walking aids observed at 4 weeks after 
treatment in all groups
Statistically significant difference in number of patients reporting reduced 
dependence on aids in Arm 3 (P = 0.0100) and Arm 4 (P = 0.0000) 
compared with Arm 1
Calf spasticity (MAS scores differences at each assessment vs. baseline)
In all groups, spasticity decreased throughout the 12-week study period
Greatest improvements in spasticity vs. PBO in Arm 4, at all time points (4 
weeks: P = 0.012; 8 weeks: P = 0.017; 12 weeks: P = 0.019) 
Safety outcomes:
AEs per group (PBO, 
500 U, 1,000 U, 1,500 U):
29%, 29%, 25%, 33%
Severe AEs per group: 
PBO: 5 
(1 pain, 1 edema, 
1 paraesthesia, 
1 hypertonia, and 1 
pancreatitis)
500 U: 2 
(1 pharyngitis, 
1 Dysphagia)
1,000 U: 3 
(1 headache, 
1 somnolence, 
1 dizziness)
1,500 U: 5 
(2 pain, 1 asthenia, 
1 somnolence, 
1 abnormal gait)
Mild to Moderate AEs per 
group (PBO, 500 U, 
1,000 U, 1,500 U):not 
consistently related to 
treatment. Those 
occurring at a frequency 
of 5% or greater (3  
patients per group)
Pain 
(7.3%, 8.5%, 8.3%, 
10%)
Asthenia 
(0, 0, 0, 8.3%)
Convulsion 
(0, 5.1%, 0, 0)
Myasthenia 
(0, 0, 5%, 0)
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TABLE 2. (Continued)
Study Identifier
Design, Objective
Patient Population, 
Sample Size
Intervention Efficacy Outcomes Safety Outcomes
Gusev et al., 2008
Design: 
Randomized, double-
blind, placebo-
controlled trial
Objective: 
To assess the 
efficacy of ABO in the 
treatment of adults 
with adductor muscle 
spasticity due to 
definite or probable 
multiple sclerosis
Patient population:
Hip adductor spasticity 
in MS
Sample size:
N = 106
Intervention:
Arm 1: PBO
Arm 2: ABO (1,000 
U or 1,500 U)
Note: ABO dose 
modified according to 
degree of spasticity, 
asymmetry of 
spasticity, variations of 
body and muscle mass, 
and previous 
experience with BoNT
Primary outcome: 
Improvement in patient-selected functional outcome measure at week 4
The outcome most patients (ABO and PBO groups) selected and wanted to 
most improve was “dressing of lower body” 
Second and third patient choices were “maintenance of perineal hygiene” 
and “transfer to toilet”
The majority of patients in both treatment groups reported “great deal of 
difficulty” performing their chosen outcome measure (ABO 40% vs. PBO 
39%, reports NS, P value NR)
Secondary outcomes:
Key functional outcome measure (patient selected) at weeks 4, 8 and 12: 
Responder (showing an improvement in at least one point from baseline)
At week 4, 29% of patients in both treatment groups reported an 
improvement of 1 grade in their key functional outcome measure (NS, 
P = 0.745); significance was not reached by week 8 or 12 (NS, P = 0.469 
and P = 0.497)
Treatment response for “maintenance of perineal hygiene” trended toward 
but did not reach significance (ABO 40% vs. PBO 24%, NS, P = 0.096)
Changes in MAS in both legs
Some improvement in MAS response rates was seen at all time points 
(weeks 4, 8, and 12) for ABO-treated patients compared with PBO (NS, P 
value NR)
At week 8, the proportion of patients who had an improvement of  1 point 
on the MAS for leg adductor muscle tone approached but did not reach 
significance (NS, P = 0.067)
Changes in distance between knees under passive and active abduction
Distance between knees increase under passive and active abduction for
ABO-treated patients was greater than compared with PBO, but did not 
reach significance (NS, P value NR)
Retreatment
Retreatment was indicated or requested by more ABO treated patients 
compared with PBO (53% vs. 49%, P value NR)
Safety outcomes:
AEs observed in 53% of 
ABO treated patients 
compared with 27% of 
PBO treated patients; P
value NR
Most AEs mild to 
moderate intensity and 
resolved in a few days
Most frequent AEs:
Asthenia (ABO:22% vs. 
PBO: 6%; P value NR)
Pain, hypertonia and 
dry mouth reported
more often in the ABO 
group compared with 
PBO (data and P value 
NR)
Serious AEs possibly due 
to ABO:
One ABO treated patient 
had mild asthenia, 
moderate dysphasia, and 
moderate dysarthria
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TABLE 2. (Continued)
Study Identifier
Design, Objective
Patient Population, 
Sample Size
Intervention Efficacy Outcomes Safety Outcomes
Hyman et al., 2000
Design: 
Randomized, double-
blind, placebo-
controlled dose-
ranging study
Objective: 
To define a safe and 
effective dose of ABO 
for treating hip 
adductor spasticity
Patient population:
Hip adductor spasticity 
in MS
Sample size:
N = 74
Intervention:
Arm 1: ABO 500 U
Arm 2: ABO 1,000 U
Arm 3: ABO 1,500 U
Arm 4: PBO
Primary outcomes:
Measure PBO
ABO
500
ABO
1,000
ABO
1,500
Distance between knees (cm)
Week 0
median 
(SD)
28.2 
(12.8)
29.8 
(12.1)
24.9
(11.9)
28.5 
(10.3)
Week 4
median 
(SD)
32.1
(12.3)
36.7
(12.8)
31.9 
(9.2)
39.2*
(10.4)
Passive hip abduction (degrees)
Week 0
median 
(SD)
42.6
(27.5)
39.4
(20.6)
39.4 
(21.3)
48.2
(23.0)
Week 4
median 
(SD)
53.9
(19.7)
56.5
(24.8)
63.4 
(24.3)
61.3
(25.4)
*P = 0.02.
Distance from the knees and passive hip abduction improved in all groups 
from week 0 to week 4; however, statistically significant improvement was 
seen only for distance between the knees in the ABO 500 group compared 
with PBO (P = 0.02)
Secondary outcomes:
Active hip abduction improved minimally across treatment groups from 
week 0 to week 4 (NS, P value NR)
MAS improved similarly across treatment groups from week 0 to week 4 
(NS, P value NR)
Muscle tone improved similarly across treatment groups, but more so with 
the increase in ABO dose (NS, P value NR)
Spasm frequency reduced similarly across all treatment groups, but more 
so in the ABO 1,000 group (NS, P value NR)
Clinical global rating improved by 1 point across treatment groups, but 
between-group comparisons, differences were not observed (NS, P value 
NR)
The proportion of pain-free (upper leg) patients across groups increased 
from week 0 to week 4 (NS, P value NR)
Hygiene improvement was not changed from week 0 to week 4 for PBO and 
ABO 500 groups; however, improvement by 1 point was seen in ABO 1,000 
and ABO 1,500 U groups (NS, P value NR)
Investigator and patient opinions of response to treatment were overall 
similar, with positive opinion for two-thirds of the ABO 500 U group and 
half of patients in the ABO 1,000 U and ABO 1,500 groups (NS, P value NR)
The highest percentage of PBO patients requested or had retreatment 
indicated before week 12 compared with the ABO-treated groups (NS, P
value NR)
Time to retreatment was significantly longer for all ABO groups (ABO 500 
U, P = 0.042; ABO 1,000 U, P = 0.017; ABO 1,500 U, P = 0.015) 
compared with PBO
Optimal dosing:
AEs:
55% of ABO-treated 
patients 
63% of PBO-treated 
patients
Most frequent AEs in ABO-
treated patients:
Hypertonia (22%)
Weakness of noninjected 
muscles (14%)
Fatigue (7%)
Urinary tract infection (5%)
Headache (5%)
Micturition frequency (5%)
Back pain (5%)
Diarrhea (5%)
The PBO group reported 
similar AEs, with the 
exception of muscle 
weakening
2 times the number of AEs 
were reported by ABO 1,500 
U group compared with the 
ABO 500 U and ABO 1,000 U 
groupsSAEs:
n = 6 reported for ABO and 
PBO
Not believed to be related to 
ABO:
n = 1 had diarrhea and 
urinary tract infection, 36 
days after receiving ABO 
1,500 U
n = 1 had urinary tract 
infection, chest infection 
and hypothermia, 69 
daysafter receiving ABO 
1,000 U
The remaining 4 SAEs were 
in the PBO group and 
resulted in hospitalizations 
due to:
Bowel spasticity
Gastropareses
Pulmonary embolism
Act = active ankle dorsiflexion; ADL = activity of daily living; AE = adverse event; AR = associated reaction; ABO = AbotulinumtoxinA; FES = functional electrical 
stimulation; FM = Fugl-Meyer score; MAS = Modified Ashworth Scale; MS = multiple sclerosis; NR = not reported; PBO = placebo; PCI = physiological cost index; 
PT = physical therapy; ROM = range of motion; Vel = Gait velocity; Vid = Video score. 
ABO¼AbotulinumtoxinA, Act¼ active ankle dorsiflexion, ADL¼ activity of daily living, AE¼ adverse event, AR¼ associated reaction,
FES¼ functional electrical stimulation, FM¼Fugl–Meyer score, MAS¼Modified Ashworth Scale, MS¼multiple sclerosis, NR¼ not reported,
PBO¼ placebo, PCI¼ physiological cost index, PT¼ physical therapy, ROM¼ range of motion, Vel¼ gait velocity, Vid¼ video score.
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em
Medicine  Volume 95, Number 2, January 2016 Botulinum Toxin in Lower Limb Spasticity(200–400 U), tibialis posterior (200–350 U), and flexor digi-
torum longus (150–300 U). Only 3 of the 23 patients reported
FIGURE 1. PRISMA flow diagram reporting the results of the systno improvement after ABO injection. There was a clear differ-
ence (P¼ 0.0014) in patients’ subjective scores between ABO
and placebo. Significant changes were noted in MAS values for
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.ankle extensors (P< 0.0001) and invertors (P¼ 0.0002) and for
active ankle dorsiflexion (P¼ 0.0001) and significant improve-
atic literature search.ments were also noted in Fugl–Meyer scores (P¼ 0.0028).
During active ankle dorsiflexion, 18/22 patients showed 1
point improvement in dorsiflexion score. Gait velocity was
www.md-journal.com | 9
slightly but not significantly improved after ABO injections.
The authors concluded that the efficacy of ABO injection in the
treatment of spastic foot suggests that ABO may be particularly
useful during the first year after a stroke.10
In an open-label study, Hesse et al11 examined the effect of
ABO with or without electrical stimulation (ES) treatment
postinjection on ALLS in 10 hemiparetic subjects with the
history of stroke. Five subjects were randomized into each
treatment group: 2000 U ABO followed by ES treatment
(30min, 6 times/d during the 3 days following the injection),
2000 units ABO without ES. Injections were performed into the
following muscles using EMG guidance: soleus, tibialis
posterior, and both heads of gastrocnemius muscles. Study
results indicated that there were no significant differences in
MAS across groups. However, the group receiving ABO þ ES
treatment demonstrated the greatest reduction in MAS
(P¼ 0.011). The result of other measures, including limb
position at rest and ability to perform 3 identified ADLs,
were variable.
The effect of combined use of ABO and functional electric
stimulation (FES) in the treatment of spastic drop foot following
stroke was also investigated by Johnson et al.12 Twenty-one
subjects participated in this nonblinded randomized controlled
study and 18 of them completed the study. Every subject
received ABO injection into the medial and lateral heads of
the gastrocnemius and tibialis posterior. Injections were per-
formed with EMG guidance. Walking speed increased in both
injection and control groups over 12 weeks study with statisti-
cally significant difference in favor of the group with FES.
Authors concluded that the combined treatment improved
walking and function.
Pittock et al evaluated the effect of ABO injections on calf
muscle hypertonicity following stroke in a prospective, multi-
center, double-blind, placebo-controlled, and dose-ranging
study. Two-hundred and thirty-four stroke patients were
randomized into the ABO group and were dosed with 500,
1000, or 1500 U.13 Within the calf, upper, and lower injection
sites were determined by palpation of the femoral and calcaneal
insertions of the gastrocnemius muscle; 1/4 and 1/3 of the total
length from the femoral insertions, respectively, and EMG
guidance was not used. The primary outcome measures, 2-
min walking distance and stepping rate, increased significantly
in each group with no significant difference between groups.
There were also small, but statistically significant improve-
ments in calf spasticity, limb pain, and reduction in the use of
walking aids compared with placebo. Authors concluded that
ABO injection resulted in a significant reduction in muscle tone,
limb pain, and dependence on walking aids. The best benefit
was achieved with 1500 U of ABO.
Hyman et al14 investigated the effectiveness and safety of
ABO for treating hip adductor spasticity. In this double-blind
study, 74 patients with multiple sclerosis and spasticity affect-
ing the hip adductor muscles of both lower limbs were recruited
and randomized to 4 groups of ABO 500, 1000, and 1500 U or
placebo. The primary efficacy variables—passive hip abduction
and distance between the knees—improved for all groups, and
the distance between the knees for the 1500 U group was
significantly greater than placebo (P¼ 0.02). Spasm frequency
was reduced in all groups, but muscle tone was reduced in the
ABO groups only. Pain was reduced in all groups, but improve-
ments in hygiene scores were evident only in the 1000 and 1500
Dashtipour et alU groups.14
Gusev et al15 also assessed the effectiveness of ABO in the
treatment of adults with adductor muscle spasticity due to
10 | www.md-journal.comdefinite or probable multiple sclerosis. In this double-blind
study, 106 subjects were recruited, and randomized to receive
injections with placebo, or ABO: 1000–1500 U in a 1:1 ratio.
The subjects received injection into adductor muscles of each
lower limb (500–750 U/leg). ABO was shown to provide
effective pain relief in patients with severe adductor spasticity.
Other predefined outcome measures, including functional per-
formance (primary outcome), did not reach statistical signifi-
cance. However, there was a significant improvement in favor
of ABO for maintenance of perineal hygiene (P¼ 0.0096) and
there were trends to significance for MAS response rates and in
the distance between knees under passive abduction.15
Table 3 shows the injection methodology and adjunct
therapies that were used in each study.
Safety in ALLS
ABO was well tolerated across the individual studies.10–15
Most adverse events reported were considered unrelated to
treatment. Adverse events considered associated with ABO
treatment included: local pain at injection site, fatigue, asthenia,
somnolence, hypertonia, dry mouth, bladder paresis, urinary
tract infection, urinary frequency, diarrhea, weakness of non-
injected muscles, headache, abnormal gait, and dysphagia. Most
of the AEs were more common at higher doses of ABO.
Dosing Across Indications
Total ABO doses ranged between 500 and 2000 U for
ALLS. The most commonly injected muscles were the triceps
surae, soleus, tibialis posterior, flexor digitrom longus, adductor
magnus, adductor longus, adductor brevis, and gastrocnemius.
Dose ranges for different muscles are summarized overall in
Table 4 and by each individual study in Table 5.
DISCUSSION
The main aim of this systematic review was to provide
guidance for physicians who manage ALLS using ABO. Other
reviews are available regarding assessment of BoNT for treat-
ment of ALLS with no emphasis on the dosing per muscles for
ABO. This is essential since the dosing units of each BoNT-A
product are not interchangeable with another toxin. In this
review, all studies showed the efficacy of ABO in spasticity
but using different outcomemeasures such asMAS, pain, or gait
velocity. All of the studies showed reductions in spasticity using
MAS, but not all of them reached statistical significance versus
placebo. This may be due to the relatively small sample sizes
employed and other study design issues. For example, most
patients in the study of ABO for hip adductor spasticity reported
by Gusev et al15 received doses that were lower than the 1500 U
dose that Hyman et al14 had previously reported to be effective.
All 6 studies included in this review used different range of
dosing that was shown to be safe and effective for the variety of
postures in ALLS. Five of the 6 studies utilized EMG guidance
as technique to optimize injection site localization and it is
unknown if the use of other localization techniques (eg, ultra-
sonagraphy) would provide substantively different results. The
dosing table provided here is based on the published studies and
does not suggest that other doses should not be applied;
physicians should always use clinical judgment on dosing
schedules based upon on the severity of impairment. A recent
international survey of routine therapeutic usage revealed that
Medicine  Volume 95, Number 2, January 2016experienced European ABO injectors report injecting doses
between 100 and 3000 U for ALLS (mean total dose
ranged from 600 to 832 U), depending on the patient’s needs.16
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 3. Injection Methodology and Adjunctive Therapies
Author Dysport Injection Methodology Adjunct Therapy
Johnson et al12 Injections were given under EMG guidance Functional electric stimulation
The Oddstock Dropped Foot Stimulator Mark III was used
Hesse et al11 EMG-guided injections Dual channel stimulator for group B patients
Hyman et al14 Muscles were located by palpation and were injected
with EMG guidance
Oral antispastic and analgesic medications being taken by
the patient at the time of entry was permitted at a constant
dose throughout the study
Standard of care physiotherapy was also permitted to
continue unchanged throughout the study
Other concomitant medications were permitted at the
discretion of the investigator
Burbaud et al10 EMG guidance Physiotherapy allowed
Gusev et al15 Muscles were located by palpation and were injected
with EMG guidance
Intrathecal baclofen was not permitted for the duration of the
study
Any existing oral antispastic medication was continued at
the same dose throughout the study and no new therapies
were started
Standard of care physiotherapy, speech therapy, and
occupational therapy could be initiated at study entry, but
wherever possible the regimen remained constant
throughout the study period
Pittock et al13 Upper calf and lower calf injection sites were determined
by palpation of the femoral and calcaneal insertions of
the gastrocnemius muscle; 1/4 and 1/3 of the total
length from the femoral insertions, respectively. EMG
guidance was not used
Use and nature of walking aids and orthoses were recorded
Concomitant medication and adjunctive treatments (eg,
physiotherapy) were allowed
Medicine  Volume 95, Number 2, January 2016 Botulinum Toxin in Lower Limb SpasticityLikewise, all 6 studies preselected only a certain number of
muscles for injection. Due to complexity of ALLS, it is vital that
the injector has a proper understanding of the patients’ indi-
vidual clinical needs. Clinical trials often prespecify muscles in
an attempt to standardize findings, but it is likely that this
restricted approach may have affected the outcome of the
studies. When deciding on dosing strategies, the injector must
consider multiple patient factors such as the muscles affected,
patient functionality, size of the patient, residual deficit, and the
etiology of the spasticity. For example, whereas some patients
with poststroke spasticity may gradually improve their function
with proper rehabilitation, patients with spasticity secondary to
central neurodegenerative disorders will usually worsen. In
patients with multiple sclerosis, the degree of deficit is subject
TABLE 4. Dose Range of ABO for Each Individual Muscle
Muscles Dose Range, U
Triceps surae 500–1000
Soleus 200–500
Tibialis posterior 200–500
Flexor digitorum longus 150–300
Gastrocnemius medial 200–500
Gastrocnemius lateral 200–500
Adductor magnus 250–375
Adductor brevis 125.0–187.5
Adductor longus 125.0–187.5
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.to remission and exacerbation. Each of these different disease
states requires a different dosing approach. Overall, additional
research is needed in order to better define the optimal ABO
dose and dilution parameters for individual muscles, the number
and location of injection sites, and the most suitable technique
for injection localization (eg, surface anatomy, EMG guidance,
ES, and ultrasonography).
The degree of functional impairment is 1 of the most
important factors to consider for managing spasticity. Unfortu-
nately, spasticity research is hampered by the lack of outcome
measures that are able to properly assess functional impairment
before and after toxin injection,17 and this methodological
limitation was evident in these 6 studies as well. For many
patients, the impact of ALLS on their walking ability and gait
significantly impacts their safety, comfort, social integration,
and quality of life.18 Speed of gait was included in all 4 of the
poststroke studies included in this review; however, statistical
differences between ABO and placebo were difficult to show
despite the fact that tone was consistently decreased after ABO
injection.10–13 As Burbaud and colleagues note, there are many
factors that can affect speed of gait—for example, a poststroke
patient who no longer requires a walking stick or ankle orthosis
to help them walk may walk more slowly because they are
cautious of their regained ability.10 Further, it is worth noting
that significant effects on speed of gait seemed to rely on the
presence of concomitant physiotherapy. Whereas all patients in
the Hesse study (which found a positive effect on speed of gait)
had concomitant physiotherapy,11 only 38% of patients in the
trial reported by Pittock et al received any physiotherapy (and,
of these, most only received 1 session).13 It is important to note
www.md-journal.com | 11
listed on clinicaltrials.gov (including a double-blind study with
ferred to review the effectiveness of ABO in each study
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12 | www.md-journal.comthat many factors affect can impact functional outcomes. For
example, as Burbaud and colleagues note, a lack of improve-
ment in gait velocity could also reflect a detrimental effect of
the toxin, which might produce too much weakness in plantar
flexion.10 Gusev and colleagues note that if toxin spreads and
weakens muscles adjacent to leg adductors, it is conceivable
that the weakness could have negative influenced the ability to
perform functional tasks with the legs.15 Such observations
confirm the need for a highly individualized and multidisci-
plinary approach to manage ALLS, where functional outcomes
and physical intervention are vital for achieving patient-specific
treatment goals. Future research should also consider measure-
ment of activity-based outcomes, such as total step count
profiles, which have been found to be useful when assessing
for meaningful changes in ambulatory performance in patients
with spinal cord injury, spinocerebellar ataxias, and chronic
stroke.19–21
This systematic literature review is part of a larger review
where the use of ABO in other indications such as AULS has
also been evaluated.8 When comparing the present results with
the strength of the literature for AULS, it is apparent that more
high-quality studies are required to inform practice. This need
for more research is not limited to the use of ABO in ALLS, but
there is also a clear and urgent need to better understand the
burden of the condition2 and also the effectiveness of other
treatments (including other BoNT formulations).22 Such work is
ongoing and over 10 clinical trials of interventions for ALLS are
Medicine  Volume 95, Number 2, January 2016ABO NCT01249404 and its open label extension study
NCT01251367).
LIMITATIONS
This systematic review employed strict inclusion criteria
as described in the Cochrane Handbook for Systematic
Reviews of Interventions Version 5.1.0.23 Based on our criteria
a large number of uncontrolled, exploratory studies were
excluded and affected our sample size. While this obviously
eliminated some clinically relevant information, this estab-
lished methodology is considered necessary to avoid bias by
using explicit, systematic methods. A key aim of this systema-
tic review was to produce a comprehensive, evidenced-based
data report that provides information on the injection schema
used and associated outcomes for ABO in ALLS. However, the
substantial heterogeneity among patients included in these 6
studies regarding their geographical location, etiology and
severity of spasticity significantly limits our ability to draw
firm conclusions. The heterogeneity of outcome measures
made it difficult to directly compare studies, and so we pre-separately. Another limitation is due to lack of long follow
up after ABO injection.
CONCLUSIONS
This systematic review provided current evidence regard-
ing safety and efficacy of ABO injection for ALLS. Based on
the evidence reviewed, it can be concluded that ABO injections
consistently reduce tone and can be effectively employed in the
management of ALLS of various etiologies. However, the
review also revealed lack of large trials of ABO to manage
ALLS, and highlighted the need for future trials to employ
relevant outcome measures that properly assess patients’
functional ability.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
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